Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.

"Disclosures Dr. Laura Esserman is leading an investigator-initiated vaccine trial for high-risk ductal carcinoma in situ which is funded by Merck through the University of California San Francisco."

"RAM contributed to the study conception and design. Material preparation, data collection and analysis were performed by RAM and HTR. The first draft of the manuscript was written by HTR and all authors read and approved the final manuscript. RAM was supported by the National Cancer Institute Award K08CA256047. HTR was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number TL1 TR 001871. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH."